Modeled DDIs for phenytoin

Overview of the modeled DDIs for phenytoin. Black arrow means sensitive victim in the specific metabolic pathway for phenytoin (CYP2C9 and CYP2C19) and itraconazole (CYP3A4). Red curve line means inhibition, e.g., fluconazole is a competitive inhibitor of phenytoin’s CYP2C9- and CYP2C19-mediated metabolism. Omeprazole inhibits the CYP2C19-mediated enzymatic conversion of phenytoin via competitive inhibition and mechanism-based inactivation (MBI). Green curve means the induction, e.g., phenytoin induces the CYP3A4-mediated enzymatic biotransformation of itraconazole.
Modeled DDIs for phenytoin

Publication

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin (2023) Leyanis Rodriguez-Vera, et al. Pharmaceutics. 2023 Oct;15(10). Figure: F2.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates CYP2C9 CYP2C9 ncbigene_symbol CYP2C9 1559
Homo sapiens Primates CYP2C19 CYP2C19 ncbigene_symbol CYP2C19 1557
Homo sapiens Primates CYP3A4 CYP3A4 ncbigene_symbol CYP3A4 1576
Homo sapiens Primates MBI MBI ncbigene_synonym SCARNA10 692148

Chemical mentions

Word Match MeSH Name ChEBI
Phenytoin phenytoin 5,5-diphenylimidazolidine-2,4-dione chebi:8107
Fluconazole fluconazole fluconazole chebi:46081
Omeprazole omeprazole rac-5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole chebi:7772

Disease mentions

Word Match MeSH Name DOID